Northpointe Bancshares, Inc.

NYSE:NPB

Banks - Regional

Financial Services
$14.79 +0.11%

+$0.02 today

Market cap
$511.47M
Beta
0.11
P/E (TTM)
3.1
EPS (TTM)
$5.85
Dividend yield
0.56%
52W Low $12.95High $19.48

Volume 0.33M

Average 0.15M

NPB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Northpointe Bancshares, Inc.NYSE: NPB

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development remains negative

Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How NPB compares with its peers on the latest reported figures

  • NPB's LTM Mar 2026 research & development of $0 is the lowest of the 7 companies compared; the peer median is $160.83M.
  • Research & development amounts to 0.0% of revenue for NPB, versus a peer median of 52.7%.
NPB Competitors Peer median
Research & Development for NPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$378.58M -9.4%+7.3%27.9%
ZLABZai Lab LimitedLTM Jun 2026$236.92M +3.2%-8.3%52.7%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$188.07M +22.3%+26.8%—
ERASErasca, Inc.LTM Sep 2026$133.6M +39.6%-6.2%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M -11.6%-4.0%291.9%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$66.71M -38.5%-7.9%—
NPBNorthpointe Bancshares, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding NPB) $160.83M-3.1%-5.1%52.7%

Competitors are the stored peer set for NPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.17M324.24M362.45M390.46M471.18M
Cost of Revenue1.14M68.9M164.68M202.99M231.56M
Gross Profit1.02M255.34M197.77M187.47M239.62M
Gross Margin47.3%78.7%54.6%48.0%50.9%
Research & Development29.88M0000
Selling, General & Admin22.17M159.88M104.29M77.79M93.62M
Operating Expenses52.05M221.65M153.08M114.59M129.23M
Depreciation & Amortization840.94K4.02M4.02M3.8M3.07M
EBITDA(56.67M)37.71M48.7M76.68M113.47M
EBITDA Margin-2613.5%11.6%13.4%19.6%24.1%
Operating Income(51.03M)33.69M44.69M72.88M110.39M
Operating Margin-2353.1%10.4%12.3%18.7%23.4%
Interest Income525.54K166.12M267.38M317.53M380.2M
Interest Expense066.69M166.16M203.32M229.47M
Other Income / Expenses(6.49M)0000
Income Before Tax(57.52M)33.69M44.69M72.88M110.39M
Pre-Tax Margin-2652.3%10.4%12.3%18.7%23.4%
Income Tax Expense(77.7K)10.46M10.93M17.72M26.98M
Net Income(57.44M)23.24M33.76M55.16M83.41M
Net Margin-2648.7%7.2%9.3%14.1%17.7%
EPS (Basic)(1.74)0.921.613.154.92
EPS (Diluted)(1.74)0.921.613.154.85
Weighted Avg Shares33.03M14.92M14.92M14.92M14.54M
Weighted Avg Shares (Diluted)33.03M14.92M14.92M14.92M14.72M

Northpointe Bancshares, Inc.

NYSE:NPB

Intrinsic Alpha fair value

Locked

Current Price

$14.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.